Interestingly, despite early response to therapy, this patient unfortunately developed rapidly progressive metastatic disease while actively receiving adjuvant nivolumab and was found to have acquired a MYC amplification that was not present on his baseline biopsy. The gene discussed is MYC; the disease is metastatic neoplasm.